Myriad Genetics Files Suit Against BioReference Labs. - Quick Facts

(RTTNews) - BioReference Laboratories Inc. (BRLI) reported that Myriad Genetics (MYGN) has filed a lawsuit against it in the Federal District Court in Utah stating that BioReference, via. its genetic sequencing laboratory, GeneDx, Inc, is infringing on its intellectual property by offering OncoGeneDx, its comprehensive series of inherited cancers testing, including testing for BRCA1/2. Further, BioReference said it is not surprised by the action and that it is confident in its position.

BioReference has engaged the firm of Sterne, Kessler, Goldstein & Fox to represent it in the action. BioReference added that the test was launched in August of this year, after careful consideration in view of the Supreme Court's recent decisions in the field of genetic diagnostics.

As usual, for BioReference, the tests would be based on innovative technology, would be affordable, and would be designed to provide the service and support that has enabled BioReference to maintain its sustained growth for the past couple of decades.

Myriad Genetics has taken similar steps to defend its exclusivity for BRCA1/2 testing by suing other laboratories that offer BRCA1/2 testing. The latest action against BioReference is not unexpected and the company is prepared to defend against the action. BioReference said it is confident in its legal position and its belief that patients are better served in this evolving area of medicine by having choices and better access to alternative testing sources.